GlassScriptPhysician profile
Dwight D Generoso
NPI 1831812544
$1,934.63
in general payments reported to CMS, 2019-2025
21 companies · $1,090 in 2025
The $1,090 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $66.78 · 2023: $597 · 2024: $182 · 2025: $1,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,868.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,867.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $479.43 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $215.08 | 2023-2025 | |
| Agios Pharmaceuticals, INC. | $184.77 | 2025 | Pyrukynd |
| Novo Nordisk INC | $139.62 | 2023-2025 | Alhemo, Rebinyn, Tretten |
| Chiesi USA, INC. | $131.15 | 2023-2025 | Ferriprox, Kengreal |
| Spark Therapeutics, INC. | $124.97 | 2023 | |
| Pfizer INC. | $96.61 | 2023-2025 | |
| Emmaus Medical, INC. | $84.84 | 2023-2024 | Endari |
| Medexus Pharma, INC. | $78.63 | 2024-2025 | Ixinity |
| Hema Biologics, LLC | $56.58 | 2025 | Sevenfact |
| Biomarin Pharmaceutical INC. | $49.02 | 2025 | Roctavian |
| Kedrion Biopharma, INC. | $47.62 | 2024-2025 | Koate, Kedrab, Gammaked |
| Takeda Pharmaceuticals U.S.A., INC. | $41.42 | 2023-2025 | Adynovate, Vonvendi |
| Csl Behring | $39.19 | 2023-2025 | Humate-P, Idelvion |
| Octapharma USA, INC. | $28.72 | 2025 | Wilate - Von Willebrand Factor/Coagulation Factor Viii Complex (Human) |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $26.88 | 2023 | Hemlibra |
| Biohaven Pharmaceutical Holding Company LTD. | $24.55 | 2022 | |
| Ucb, INC. | $24.51 | 2022 | |
| Rare Disease Therapeutics, INC. | $22.72 | 2025 | Xromi |
| Genentech, INC. | $20.60 | 2025 | Hemlibra |
| Acadia Pharmaceuticals INC | $17.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dwight Generoso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.